Skip to main content
. 2021 Nov 17;7(3):e001818. doi: 10.1136/rmdopen-2021-001818

Table 3.

Summary of results for reporting and analysing for follow-up information and handling of attrition

Main analysis DS1 DS2
N 211 131 115
Reporting of patients lost to follow-up 69 (33%) 47 (36%) 44 (38%)
Reporting of patients lost to follow-up by treatment 30 (14%) 26 (20%) 24 (21%)
Reporting of patients changing/stopping treatment 101 (48%) 75 (57%) 64 (56%)
Reporting of reasons for treatment discontinuation 62 (29%) 47 (36%) 41 (36%)
Handling of attrition in the analysis (in studies with outcome other than retention) 44/177 (25%) 31/106 (29%) 28/95 (29%)
Method to handle attrition (when acknowledged)*
Non-responder imputation 27/44 (62%) 22/31 (71%) 20/28 (72%)
Complete case 8/44 (18%) 5/31 (16%) 5/28 (18%)
Last observation carried forward 8/44 (18%) 4/31 (12%) 2/28 (7%)
Other 8/44 (18%) 7/31 (23%) 6/28 (21%)

DS1: Dataset 1 includes only studies where the comparison of at least two treatments was the main exposure of interest (head to head studies).

DS2: Dataset 2 includes only studies from DS1, which had no other outcome than effectiveness.

*Sum of the methods may be greater than the numbers of studies as some studies used several methods.